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ABSTRACT 
Introduction. Anticoagulants are commonly indicated in cirrhotic patients due to 
high rate of (pro)thrombotic conditions. Low molecular weight heparin (LMWH) is 
safe in patients with esophageal varices. However, the safety of LMWH is unknown 
in patients undergoing prophylactic endoscopic variceal ligation (EVL). 
Aim. To define the 4-week risk of bleeding and death after prophylactic EVL in 
cirrhotic patients continuously treated with LMWH. 
Methods. All EVLs performed at a tertiary Italian Center from 2009 to 2016 were 
retrospectively reviewed. Patients treated with LMWH were classified as on-LMWH; 
the remaining as no-LMWH. Endoscopic characteristics at first and index EVL (that 
preceding an endoscopy either showing a bleeding episode or the absence of further 
treatable varices) and clinical events within 4 weeks from the procedures were 
recorded.  
Results. 553 EVLs were performed in 265 patients (in 215 as a primary 
prophylaxis): 169 EVLs in 80 on-LMWH and 384 in 185 no-LMWH (4.9±1.1 vs. 
4.8±1.0 bands/session, respectively; p=0.796). Six patients bled (2.2%) without 
between-groups difference (3.8% on-LMWH vs. 1.6% no-LMWH, Log-rank p=0.291). 
Large varices with red marks (100% vs. 51.4%, p=0.032), number of bands (5.6±0.5 
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vs. 4.6±1.2, p=0.004), underlying portal vein thrombosis (66.7% vs. 23.6%, p=0.033), 
and creatinine (2.2±2.7 vs. 1.0±0.8 mg/dl, p=0.001) at index EVL were significantly 
different between bleeders and non-bleeders. Six patients died within 4-week from 
index EVL, without between-groups difference (2.5% on-LMWH vs. 2.2% no-LMWH, 
Log-rank p=0.863). 
Conclusions. LMWH does not increase the risk of post-procedural bleeding and 
does not affect survival of cirrhotic patients undergoing prophylactic EVL. 
 
Keywords 
Endoscopic Variceal Band Ligation; Low Molecular Weight Heparin; Short-term Risk 
of Bleeding.  
 
Key point box 
 Anticoagulants are frequently indicated in cirrhotic patients to treat portal vein 
thrombosis (PVT) or other (pro)thrombotic conditions. 
 Low molecular weight heparin (LMWH) is often indicated as a bridge 
anticoagulant in patients undergoing endoscopic procedures. 
 It is not known if LMWH increases the bleeding risk associated to prophylactic 
endoscopic variceal ligation (EVL). 
 This study shows that anticoagulant treatment with LMWH does not increase the 
short-term risk of bleeding and death after EVL in cirrhotic patients.  
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
INTRODUCTION 
Recent data on the coagulative status of patients with liver cirrhosis show that they 
are prone to thrombotic 1 as well as hemorrhagic events 2,3 and that thrombotic 
events are more frequent in these patients than in the general population 4,5. 
Compared to thrombosis in peripheral veins, portal vein thrombosis (PVT) is a 
complication of cirrhosis that can cause both a worsening of portal hypertension and 
a reduced perfusion of the liver with serious consequences in patients with 
esophagogastric varices at risk of bleeding and impaired liver function 4,5. First line 
treatment in these cases is anticoagulation, which includes low molecular weight 
heparin (LMWH) 4,5. LMWH has also been used to prevent PVT in cirrhotic patients 
with esophagogastric varices obtaining an unexpected favorable impact on the risk 
of decompensation and death 6. 
It has been demonstrated that anticoagulants do not increase the risk of death 
associated to acute upper-gastrointestinal bleeding in patients with cirrhosis 7. 
However, management of anticoagulation therapy in patients scheduled to 
endoscopic variceal ligation (EVL) for primary or secondary prophylaxis of variceal 
bleeding is still a matter of debate due to the lack of dedicated studies 4,5,8-10. 
Anticoagulants are frequently stopped or the endoscopic procedure is 
delayed/contraindicated fearing causal hemorrhagic complications. Major concern is 
that anticoagulants may worsen bleeding from post-banding ulcers 11,12, which, with 
a risk ranging from 0.5% to 3% in primary prophylaxis 13, frequently occurs within two 
weeks from the procedure 14,15. Available guidelines for upper endoscopic 
procedures in patients at high risk of procedure-related bleeding (which includes 
those undergoing EVL) recommend switching oral anticoagulants to LMWH during 
the peri-procedural period and restoring full anticoagulation 5 to 10 days after the 
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endoscopic treatment 16-20, when the risk of bleeding from post-banding ulcers is 
theoretically the highest. Moreover, no data are available about the safety of LMWH 
treatment administered continuously throughout more sessions of EVL until 
eradication is achieved. 
Aim of this study is to verify the 4-week risk of bleeding and death after 
prophylactic EVL in cirrhotic patients under continuous treatment with LMWH. 
 
PATIENTS AND METHODS 
Patients 
The Medical records of all patients who underwent upper endoscopy at the 
Endoscopy Unit of AOU Policlinico di Modena (Modena, Italy) from 1st January 2009 
to 30th June 2016 were retrospectively reviewed. 
Enrollment criteria were: a) histological or imaging-proven liver cirrhosis of any 
etiology, b) EVL as primary or secondary prophylaxis of variceal bleeding, c) EVL 
treatment started during the observational period. Exclusion criteria were: a) age 
below 18 or above 85 years, b) esophageal varices not well characterized at index 
endoscopy due to active bleeding causing bloody endoscopic field, c) placement of a 
transjugular intrahepatic portosystemic shunt (TIPS) for uncontrolled bleeding 21, as 
an early-TIPS 22, for intolerance/non response to NSBB 21, 23, and for concomitant 
difficult to treat ascites 21, d) EVLs performed in other hospitals during follow-up, e) 
anticoagulants started or withdrawn after first EVL. 
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Study design and definitions 
In this retrospective cohort study, demographic, endoscopic and clinical 
characteristics of the eligible patients, were collected at the time of both first and 
index EVLs (see below for the definition) (Figure 1A). Esophageal varices were 
defined as F1, F2 or F3 with or without red signs (namely red whale marks, cherry 
red spots or haematocysts) according to JRSPH classification 24. Gastric varices 
were classified according to Sarin 25. EVLs were performed with an interval of 3-4 
weeks 13, 21 until a) eradication or evidence of varices no more suitable for banding, 
b) death or liver transplantation, and c) late TIPS placement as secondary 
prophylaxis for persistent at risk varices after at least four EVL sessions 21. Success 
of EVL (that is complete eradication or presence of varices no more suitable for 
banding) was confirmed by a control EGDS performed about 3 months after the last 
non-operative endoscopy (Figure 1A). Further EGDSs were performed in patients 
with evident or suspected upper gastrointestinal bleeding. Indeed, for the purpose of 
this study, within 4 weeks EVL-related bleeding was established if either actively 
bleeding ulcers (spurting or oozing) or fresh/digested blood without other possible 
causes of digestive bleeding were documented at an EGDS performed within 12 
hours from the hemorrhage. Overall survival in the same time period was also 
calculated. Index EVL was defined as the banding session preceding a) an EGDS 
demonstrating a bleeding episode, b) an EGDS showing the absence of varices 
suitable of further ligation (applied to patients who did not bleed), and c) death, liver 
transplantation or late TIPS positioning (Figure 1A). Total mean number of bands 
was calculated as total number of used bands/total number of session/total number 
of patients. Patients already on LMWH at the time of the first banding session were 
classified as on-LMWH. Patients who had never received any anticoagulant during 
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the whole banding treatment were classified as no-LMWH. Anticoagulant dose at the 
time of EVL sessions was classified as sub coagulant (70 U/Kg subcutaneously bid) 
26, 27 or anticoagulant (100 U/kg bid) 28. In elective patients, the last dose of LMWH 
was administered at least 12 hours before the procedure. If the procedure was 
performed in the early morning, all elective patients received half daily dose of 
LMWH in the late afternoon, otherwise the treatment was restarted the following day 
26, 27. Patients taking a subcoagulant dose of LMWH during the peri-procedural 
period (i.e., from day -3 to day +1) 26, 27 received full anticoagulation (100 U/kg bid) 
for the underlying (pro)thrombotic condition in the time interval between EVL 
sessions. In non-elective patients (that is patients initially presenting with variceal 
bleeding while under anticoagulants), LMWH treatment was restarted after at least 
24 hours of demonstrated bleeding control either at a subcoagulant or anticoagulant 
dose depending on the underlying prothrombotic risk.  
When available, basal hepatic venous pressure gradient (HVPG) value was included 
if performed no more than 6 months before the first EVL session analyzed in the 
study. 
The institutional review board (Comitato Etico Provinciale di Modena) gave approval 
to retrospectively collect clinical and endoscopic data and waived the acquisition of 
informed consent from patients who were no longer being followed at the time of 
data collection (Protocol ID: 411/17). 
 
Statistical Analysis 
Student’s t test was applied to compare continuous variables, whereas chi-square 
test was performed for categorical parameters. Kaplan-Meier’s analysis was used to 
estimate the cumulative risk of bleeding and probability of survival, while Log-rank 
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test was used to compare groups. Moreover, by means of Cox regression, Hazard 
Ratios (HR) for risk of bleeding and death were calculated comparing on-LMWH and 
no-LMWH patients. A propensity score adjusted analysis by means of inverse 
probability of treatment weighted Cox regression was also performed. Propensity 
scores were the standardized individual probabilities of being on-LMWH estimated 
by logistic regression that considered baseline covariates as independent variables. 
Laboratory tests at the time of the index endoscopy were available in 177 patients, 
73 on-LMWH (91.2%) and 104 no-LMWH (56.2%); 6 bleeders (100%) and 171 non-
bleeders (66.1%).  
 
RESULTS 
In the accrual period, 27,204 upper endoscopies were performed and a total of 686 
EVLs (2.5%) on 379 patients were counted. Hundred and fourteen patients were 
excluded according to selection criteria. The majority of excluded patients had not 
well characterized varices for bloody endoscopic field at index endoscopy (N = 55) 
and TIPS placement during initial follow up (N = 29) (Figure 1B). Among the 114 
excluded patients there were 4 patients on vitamin K antagonist (VKA) and 3 on 
LMWH, whose anticoagulant treatment was withdrawn after the first EVL. 
Two hundred sixty-five patients, who received 553 EVLs, were ultimately eligible for 
the study. Of these, 215 (81.1%) underwent EVL as a primary prophylaxis.  
 
Basal Clinical Characteristics and Anticoagulation Regimens 
The majority of patients were male (70.1%) and their mean age was 61.8 years 
(median 63 years, range 24-85 years). HCV was the most frequent etiology (40.8%) 
followed by alcohol (15.5%). Forty-seven patients presented with a history of HCC 
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(17.7%). 
Eighty patients (30.1%) were maintained on LMWH during the entire period of 
eradication treatment (on-LMWH group) and underwent a total of 169 EVL sessions 
(30.5%). The remaining 185 patients (69.9%) did not receive any anticoagulants (no-
LMWH group) and underwent 384 EVL sessions (69.5%). 
 
No differences in demographic and etiologic variables were appreciated between the 
study groups (Table 1). Biochemical tests were similar with the exception of INR that 
was slightly lower in on-LMWH (1.25 ± 0.17 vs. 1.34 ± 0.22; p = 0.001). Prognostic 
scores of liver disease were similar. Basal HVPG according to selected criteria was 
performed in 119 patients, 28 on-LMWH (35%) and 91 no-LMWH (49.1%). HVPG 
levels were similar between groups. 
Main indications for anticoagulation within the on-LMWH was PVT (80%) (Table 1). 
Twenty-eight patients (35%) received a subcoagulant regimen (70 U/Kg bid), while 
the remaining 52 (65%) were treated with a full anticoagulation (100 U/Kg bid) 
(Supplementary Table 1). The subcoagulant regimen in the peri-procedural period 
was indicated in patients enrolled before year 2012. Among these there were 12 
patients primarily on the VKA warfarin at first EVL, whose INR, between 2 and 3 
before the shift to LMWH, was normalized by oral treatment with vitamin K soon after 
the shift. None of the patients reintroduced VKA during the entire eradication period 
(that is, all of them were maintained on anticoagulant dose of LMWH). Eight patients 
restarted warfarin after control EGDS (median 5 months, range 3-7 months). All of 
them were completely eradicated.  
No patients discontinued the anticoagulant treatment with LMWH throughout the 
EVL period. 
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Endoscopic Characteristics at Baseline and Follow-up 
Comparison of the endoscopic features at admission showed no differences in size 
of esophageal varices, presence of red signs, gastric varices, and portal 
hypertensive gastropathy (PHG) (Table 2). A significant higher proportion of on-
LMWH performed EVL as secondary prophylaxis compared to no-LMWH (27.5% vs. 
15.1%; p = 0.025). 
A comparison between groups at the time of the last available endoscopic check is 
summarized in Table 3. Rates of varices no more suitable of further banding were 
similar (93.8% vs. 90.8%, p = 0.479). Eight patients with persistent large varices after 
the fourth EVL session underwent late TIPS positioning as secondary prophylaxis of 
variceal bleeding; 14 more patients either died (6 of these within 4 weeks from index 
EVL, see below) or underwent liver transplant before achieving eradication. No 
differences in the number of EVL sessions and in the number of bands used were 
observed between groups.  
GOV-1 were not prophylactically ligated in this cohort. 
 
EVL-related Bleeding 
Three on-LMWH (3.75%) and 3 no-LMWH (1.62 %) experienced an episode of 
esophageal variceal bleeding after EVL, respectively. The 4-week cumulative risk of 
bleeding was similar between the study groups [p by Log-rank test = 0.291; HR = 
2.3, 95%CI = (0.5 - 11.4), p = 0.305)] (Figure 2A). Propensity score weighted 
analysis also gave similar results [HR=1.7, 95%CI = (0.2 - 21.2), p = 0.662]. As 
expected, no bleeding episodes were observed after the second week post-EVL 
(Figure 2A). Two patients bled after the first EVL session, two after the second, one 
after the third, and the last after the fourth EVL session. The 3 on-LMWH bleeders 
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were on anticoagulant dose of LMWH at the moment of the hemorrhage. Table 4 
summarizes the characteristics of the bleeders (N=6) vs. the non-bleeders (N=260). 
Main clinical and biochemical parameters, including traditional coagulation tests and 
prognostic scores for liver disease, were similar between the two groups except for 
mean serum creatinine, that was significantly higher in bleeders (Table 4). This 
higher value was determined by two bleeders, who presented with kidney failure 
(one of this, a no-LMWH patient, died 6 hours after the bleeding episode as reported 
in Supplementary Materials).  PVT was present in the majority of bleeders (N=4, 
66.7%) (Table 4). Three of these patients were on LMWH for occluding thrombosis 
since the first EVL, while the remaining was diagnosed with non-occluding 
thrombosis of the splenic vein after the post-EVL bleeding episode (no-LMWH 
patient). All bleeders showed large varices with red signs at the index EVL and 
received a significantly higher number of bands than non-bleeders (Table 4).  
No further bleeding episodes (neither gastrointestinal or in other sites) were 
registered up to the 3-month control EGDSs. 
 
Survival 
Six patients died within 28 days from the last elective banding session, 2 were on-
LMWH (2.5%) and 4 (2.2%) were no-LMWH, respectively. Short-term cumulative 
survival was similar between the study groups [p by Log-rank test 0.863; HR = 1.2, 
95%CI = (0.2 - 6.3), p=0.866) (Figure 2 B). Propensity score weighted analysis also 
gave similar results [HR = 0.9, 95%CI = (0.1-16.6), p = 0.937]. One on-LMWH and 1 
no-LMWH died 48 and 6 hours after a post-EVL bleeding episode (their medical 
history is described in Supplementary Results). Two more no-LMWH died for sepsis 
and one for end stage liver failure. The remaining on-LMWH died because of 
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hemorrhagic shock following a car accident. Long-term cumulative survival was 
similar between groups (Supplementary Figure 1). 
 
DISCUSSION 
To our knowledge, this is the first study showing that continuous LMWH treatment 
does not increase the short-term risk of bleeding and death in cirrhotic patients 
admitted to endoscopic variceal ligation either for primary or secondary prophylaxis 
of esophageal variceal bleeding. Moreover, only variables indicating the intrinsic risk 
of bleeding from varices (i.e., their size) and, consequently, the higher number of 
bands used for their obliteration appeared to be significantly linked to endoscopy 
proven hemorrhages. The presented rate of bleeding after EVL was in line with that 
reported in cirrhotic patients without both portal vein thrombosis and anticoagulation 
treatment 12, 13. While clear data connecting the coagulative status of cirrhotic 
patients and their risk of bleeding have never been consistently provided 29, variceal 
bleeding has been related to the level of portal hypertension 30 and to the endoscopic 
characteristics of varices 21,31. Our data confirm this evidence and define that there is 
no apparent causality between post EVL variceal bleeding and anticoagulant 
treatment 32. 
Anticoagulation with LMWH is considered the treatment of choice in the peri-
procedural period giving the reported higher risk of bleeding if oral anticoagulants are 
restarted sooner than 5-10 days after an operative endoscopy 16-20. However, 
guidelines are scarcely evidence-based in the setting of prophylactic EVL in cirrhotic 
patients, being mostly based on expert opinions and small case series 33. Indeed, 
timing of AVK withdrawal and imbrication with LMWH has been extrapolated from 
studies on patients undergoing colonic endoscopic polypectomy 34. This contributes 
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to explain the lack of uniformity in the management of anticoagulation in the peri-
endoscopic period worldwide 8, 20, 35, 36. In our study, 12 patients only were under 
AVK before EVL. In these patients, initial imbrication was strictly applied according to 
guidelines, including administration of vitamin K 27, but anticoagulant dose of LMWH 
were maintained thereafter until eradication was achieved (as in patients already on 
LMWH before EVL).  
LMWH has already been shown to be safe in patients with cirrhosis not 
admitted to invasive procedures 6, 28, 37. We demonstrate the safety of LMWH also in 
patients otherwise considered at high risk of bleeding for both the endoscopic 
procedure (i.e. EVL) and the underlying disease (i.e. cirrhosis further complicated by 
PVT). Although PVT increases the risk of variceal bleeding in cirrhotic patients 4, 5, 37 
and anticoagulation is indicated as its first line treatment 4,5, no clear-cut indication 
has been provided on the opportunity of performing prophylactic EVL as a 
concomitant treatment to avoid variceal bleeding 21. A recent study has shown 
prophylactic treatment with TIPS as more effective than EVL plus non-selective 
betablockers and Warfarin for the prevention of rebleeding in patients with non-
cavernomatosus PVT 38. However, in the medical treatment group anticoagulation 
was administered when eradication was already achieved (14-21 weeks after 
bleeding) and the post EVL bleeding risk was considered removed. Our results 
encourage starting PVT treatment with LMWH together with EVL for prophylaxis of 
esophageal variceal bleeding.  
Concordantly with the literature, the majority of bleeding episodes (66.6%) 
happened during the second week after EVL 11-13 both in on-LMWH and in no-
LMWH. Two (one in each group) of the 6 bleeders (33.3%) had kidney failure at the 
moment of bleeding. Moreover, EVL was not a frequent cause of death (0.7%). The 
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two patients who died for EVL-related bleeding (one of them on full anticoagulant 
dose of LMWH after shifting from warfarin) bled early after EVL (48 and 6 hours, 
respectively). Both of them had extensive thrombosis/cavernoma of portal vein and 
serious comorbidities (atrial fibrillation/obesity and kidney failure, respectively). We 
recommend a cautious evaluation of patients with similar characteristics before 
performing prophylactic EVL. 
Main limitation of this study is its retrospective, single center design. 
Moreover, although the population size was relevant for a single-center study, we 
had a low number of bleedings and deaths, which caused low statistical power. 
Furthermore, patients with HCV etiology, low Child-Pugh score and in primary 
prophylaxis were the majority of the sample. So, further prospective investigations 
focusing on patients with emerging etiologies, more advanced disease and in 
secondary prophylaxis are needed. 
In conclusion, LMWH does not increase the risk of bleeding and death in 
cirrhotic patients undergoing prophylactic endoscopic variceal ligation. Overall these 
data encourage avoiding any interruption or delay of anticoagulation treatment in 
cirrhotic patients admitted to EVL. These results will require confirmation in 
randomized trials.  
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Table 1: Comparison of baseline clinical characteristics in patients stratified 
according to anticoagulant treatment. 
Variables 
on-LMWH 
(N=80) 
no-LMWH 
(N= 185) 
p 
Male, N (%) 55 (68.8) 131 (70.4) .784 
Age (years) * 63.5±12.1 61.1±11.5 .138 
Etiology, N (%) 
Viral 
HCV 
HBV 
EtOH 
NASH  
 
41 (51.2) 
33 (41.2) 
8 (10) 
8 (10) 
8 (10) 
 
91 (48.9) 
76 (40.9) 
15 (8.1) 
35 (18.8) 
9 (4.8) 
 
.728 
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PBC 
Others 
5 (6.3) 
18 (22.5) 
9 (4.8) 
41 (22) 
HCC, N (%) 17 (21.2) 30 (10.8) .381 
Ascites, N (%) 
Grade 1-2 
Grade 3 
 
5 (6.3) 
3 (3.8) 
 
20 (10.8) 
3 (1.6) 
 
.303 
HE, N (%) 3 (4.2%) 8 (6.1) .720 
Comorbidities, N (%) 
Cardiovascular 
Diabetes 
Chronic Kidney Disease 
 
19 (23.8) 
20 (25.0) 
2 (2.5) 
 
30 (16.2) 
44 (23.8) 
4 (2.1) 
 
 
.455 
 
MAP (mmHg) * 85±10.6 87±12.3 .364 
Haemoglobin (g/dl) * 11.5±2.2 11.9±2.05 .227 
WBC (103/mm3) * 4.60±2.62 5.10±3.00 .198 
Platelets (103/mm3) * 84.1±63.2 88.1±48.2 .630 
INR * 1.25±0.17 1.34±0.22 .001 
Albumin (g/dl) * 3.31±0.72 3.35±0.78 .737 
Bilirubin (mg/dl) * 1.53±1.06 1.95±2.55 .172 
Creatinine (mg/dl) * 1.04±0.62 1.00±0.81 .707 
Child-Pugh score * 6.5±1.5 6.4±1.6 .785 
MELD score * 11.2±3.1 12.2±4.7 .053 
HVPG (mmHg) * 16.9±8.2° 18.3±5.6°° .288 
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On NSBB, N (%) 31 (38.8) 75 (40.5) .290 
On NSBB primarily for Cardiovascular Indications, N (%) 6 (7.5) 12 (6.5) .675 
Started NSBB as Secondary Prophylaxis, N (%) 22 (27.5) 28 (15.1) .025 
Started Endoscopic Primary Prophylaxis for HVPG non-
response to NSBB, N (%)@ 
3 (3.8)§ 35 (18.9) .001 
Started Endoscopic Secondary Prophylaxis, N (%) 22 (27.5) 28 (15.1) .025 
Already on proton pump inhibitors, N (%) 18 (22.5) 35 (18.9) .507 
Started proton pump inhibitors, N (%) 21 (26.2) 43 (23.2) .640 
Anticoagulation Regimen at the time of EVL, N (%) 
Subcoagulant** 
Anticoagulant*** 
 
28 (35) 
52 (65) 
- - 
Indication for LMHW, N (%) 
PVT 
Atrial Fibrillation 
Pulmonary Embolism 
Deep-vein Thrombosis 
Prosthetic Mechanic Heart Valve 
 
64 (80) 
7 (8.7)# 
3 (3.7)# 
5 (6.3)# 
1 (1.3)# 
- - 
PVT features, N (%) 
Portal Trunk 
Spleno-portal 
Meso-portal 
Spleno-mesenteric 
Lumen occlusion >50% 
Significant vascular recanalization at time of first EVL  
 
41 (64.1) 
7 (10.9) 
8 (12.5) 
8 (12.5) 
39 (60.9) 
9 (14.1) 
- - 
 
*: mean ± SD;  
**: 70 U/Kg subcutaneously bid;  
***: 100 U/kg subcutaneously bid;  
°: 28/80;  
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°°: 91/185;  
#: 12 out of 16 patients without PVT were primarily on VKA;  
@: All these patients underwent the first EVL the day after HVPG assessment;  
§: All these patients had already shown significant decrease of thrombosis at the 
moment of hemodynamic evaluation, but they were maintained on LMWH throughout 
the EVL sessions. 
Abbreviations: EtOH, ethanol; HBV, hepatitis B virus; HCC, hepatocellular 
carcinoma; HCV, hepatitis C virus; HE, hepatic encephalopathy; H-R, heart rate; 
HVPG, hepatic venous pressure gradient; INR, international normalized ratio; 
LMWH, low molecular weight heparin; MAP, mean arterial pressure; NSBB, non-
selective beta-blockers; PBC, primary biliary cirrhosis; PVT portal vein thrombosis; 
VKA, Vitamin K antagonist; WBC, white blood cells. 
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Table 2: Comparison of baseline endoscopic characteristics in patients stratified 
according to anticoagulant treatment. 
Variables 
on-LMWH 
(N=80) 
no-LMWH 
(N=185) 
p 
Esophageal Varices, N (%) 
F1 
F1 with red signs 
F2 
F2 with red signs 
F3 
F3 with red signs 
 
0 
10 (12.5) 
11 (13.8) 
35 (43.7) 
2 (2.5) 
22 (27.5) 
 
0 
11 (5.9) 
41 (22) 
98 (53) 
4 (2.2) 
31 (16.7) 
 
.860 
Gastric Varices, N (%) 
GOV-1 
GOV-1/GOV-2 or IGV-1 
GOV-2 
IGV-1 
 
25 (31.3) 
4 (5.0) 
8 (10.0) 
3 (3.8) 
 
45 (24.3) 
8 (4.3) 
18 (9.7) 
9 (4.9) 
.791 
PHG, N (%) 70 (87.5) 161 (87) 1.0 
 
Abbreviations: GOV-1, Gastroesophageal Varices type 1; GOV-2, Gastroesophageal 
Varices type 2; IGV-1, Isolated Gastric Varices Type 1; PHG, portal hypertensive 
gastropathy. 
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Table 3: Comparison of endoscopic characteristics at last available EGDS# in 
patients stratified according to anticoagulant treatment. 
Variables on-LMWH  
(N=80) 
no-LMWH  
(N=185) 
p 
Esofageal Variceal not suitable of 
further banding, N (%) 
75 (93.8) 168 (90.8) .479 
Esophageal Varices, N (%) 
F1 with red signs 
F2 
F2 with red signs 
F3 
 
1 (1.3) 
3 (3.8) 
1 (1.3) 
0 
 
1 (0.5) 
12 (6.5) 
2 (1.1) 
2 (1.1)  
 
 
.543 
 
 
Persistent Large Esophageal Varices 4 (5) 16 (8.6) .447 
Gastric Varices, N (%) 
GOV-1 
GOV-1/GOV-2 or IGV-1 
GOV-2 
IGV-1 
 
23 (28.8) 
2 (2.5) 
8 (10.0) 
3 (3.8) 
 
39 (21.1) 
5 (2.7) 
19 (10.3) 
9 (4.9) 
 
.819 
PHG, N (%) 65 (81.3) 163 (88.1) .139 
Mean EVL Sessions * 2.1±1.2 2.0±1.1 .441 
Number of Bands °* 4.7±1.2 4.6±1.1 .756 
Total Mean Bands °°* 4.8±1.0 4.7±0.9 .532 
 
#: For the majority of patients (75/80 and 168/185 for on-LMWH and no-LMWH, 
respectively) last available EGDS was the 3-month control endoscopy. For the 
remaining patients was the procedure before death, liver transplantation and late 
TIPS positioning. 
*: mean ± SD;  
°Number of bands used at the last EVL session; 
°°Total Mean Bands = (Total number of bands/Total number of EVL 
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sessions)/Number of Patients. 
Abbreviations: EGDS, esophagogastroduodenoscopy; GOV-1, Gastroesophageal 
Varices type 1; GOV-2, Gastroesophageal Varices type 2; IGV-1, Isolated Gastric 
Varices Type 1; PHG, portal hypertensive gastropathy. 
 
Table 4: Comparison of clinical and endoscopic characteristics at index EGDS# in 
patients stratified according to post-EVL esophageal varices bleeding.  
Variables 
Bleeders@ 
(N=6) 
Non Bleeders@ 
(N=259) 
p 
Age* 47.6±11.3 62.1±11.5 .003 
Albumin (g/dl) * 3.54±1.03 3.42±0.60 .788 
Bilirubin (mg/dl) * 2.21±2.64 1.87±2.27 .720 
INR * 1.30±0.22 1.30±0.21 .960 
Platelets (103/mm3) * 98.3±58.7 86.8±53.3 .604 
Creatinine (mg/dl) * 2.2±2.7** 1.0±0.8 .001 
Hemoglobin (g/dl) * 11.8±2.3 11.9±1.9 .904 
MELD score * 15.1±6.9 11.8±4.1 .056 
Child-Pugh score * 6.4±1.6 6.3±1.6 .699 
PVT, N (%) 4 (66.7)§ 61 (23.6) .033 
HCC, N (%) 0 (0) 47 (18.4) .595 
On proton pump inhibitors, N (%) 4 (66.7) 113 (43.6) .410 
Esophageal Varices, N (%) 
F1 
F1 with red signs 
F2 
F2 with red signs 
 
0 (0) 
0 (0) 
0 (0) 
2 (33.3) 
 
19 (7.3) 
50 (19.3) 
51 (19.7) 
107 (41.3) 
 
.289 
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#: Index EVL was defined as the banding session preceding a) the EGDS 
demonstrating a bleeding episode; b) the EGDS that showed the absence of varices 
suitable of further ligation, and c) death, liver transplantation or late TIPS positioning 
(Figure 1A). 
@Laboratory tests at the time of the index endoscopy were available in 177 patients, 
73 on-LMWH (91.2%) and 104 no-LMWH (56.2%); 6 bleeders (100%) and 171 non-
bleeders (66.1%).  
*: mean ± SD.  
**: creatinine levels higher than the upper limit of normality were detected in 2 out of 
6 patients.  
F3 
F3 with red signs 
0 (0) 
4 (66.7) 
6 (2.3) 
26 (10) 
Large Varices with red signs, N (%) 6 (100) 133 (51.5) .031 
Gastric Varices, N (%) 
GOV-1 
GOV-1/GOV-2 or IGV-1 
GOV-2  
IGV-1 
 
2 (33.3) 
1 (16.7) 
1 (16.7) 
0 (0.0) 
 
60 (23.2) 
5 (1.9) 
27 (10.4) 
12 (4.6) 
 
 
.329 
 
PHG, N (%) 5 (83.3) 223 (86.1) .598 
Mean EVL Sessions * 2.5±1.1 2.1±1.0 .335 
Number of Bands 5.67±0.5 4.6±1.2 .004 
Total Mean Bands° * 5.4±0.4 4.7±1.0 .023 
On Endoscopic Secondary 
Prophylaxis, N (%)    
1 (16.7) 49 (18.9) 1.0 
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°: Total Mean Bands = (Total number of bands/Total number of EVL 
sessions)/Number of Patients. 
§: these patients had a thrombosis demonstrated by imaging at the time of bleeding. 
Abbreviations: EGDS, esophagogastroduodenoscopy; GOV-1, Gastroesophageal 
Varices type 1; GOV-2, Gastroesophageal Varices type 2; IGV-1, Isolated Gastric 
Varices Type 1; HE, hepatic encephalopathy; HCC, hepatocellular carcinoma; INR, 
international normalized ratio; PHG, portal hypertensive gastropathy; PVT portal vein 
thrombosis.  
 
FIGURE LEGENDS 
Figure 1 
A) Study design. EVLs were performed with an interval of 3-4 weeks. Eradication 
control was performed about 3 months after the last endoscopic evidence of a 
successful EVL. B) Cohort of patients included in the study. 
Abbreviations: EGDS, esophagogastroduodenoscopy; EVL, endoscopic variceal 
ligation; HVPG, hepatic venous pressure gradient; LABs, laboratory tests; LMWH, 
low molecular weight heparin; LT, liver transplant; MELD, Model for End-Stage Liver 
Disease; TIPS, transjugular intrahepatic porto-systemic shunt. 
 
Figure 2 
A) Cumulative risk of short term esophageal variceal bleeding in the study groups. B) 
Short-term survival of study groups. No patient underwent liver transplantation during 
the reported follow up. 
Abbreviation: LMWH, low molecular weight heparin. 
Supplementary Figure 1  
Long-term survival of the study groups (follow-up range 0.1-90 months; median 8.47 
months). Patients who underwent liver transplantation (n=41) were censored as 
alive.  
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